AU6244190A – Bile acid derivatives, processes for their preparation, and use as pharmaceuticals
– Google Patents
AU6244190A – Bile acid derivatives, processes for their preparation, and use as pharmaceuticals
– Google Patents
Bile acid derivatives, processes for their preparation, and use as pharmaceuticals
Info
Publication number
AU6244190A
AU6244190A
AU62441/90A
AU6244190A
AU6244190A
AU 6244190 A
AU6244190 A
AU 6244190A
AU 62441/90 A
AU62441/90 A
AU 62441/90A
AU 6244190 A
AU6244190 A
AU 6244190A
AU 6244190 A
AU6244190 A
AU 6244190A
Authority
AU
Australia
Prior art keywords
bile acid
substance
acid residue
acid derivatives
absorbed
Prior art date
1989-09-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU62441/90A
Other versions
AU637822B2
(en
Inventor
Werner Kramer
Gunther Wess
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1989-09-14
Filing date
1990-09-13
Publication date
1991-03-21
1990-09-13
Application filed by Hoechst AG
filed
Critical
Hoechst AG
1991-03-21
Publication of AU6244190A
publication
Critical
patent/AU6244190A/en
1993-06-10
Application granted
granted
Critical
1993-06-10
Publication of AU637822B2
publication
Critical
patent/AU637822B2/en
2010-09-13
Anticipated expiration
legal-status
Critical
Status
Expired
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D213/81—Amides; Imides
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P3/00—Drugs for disorders of the metabolism
A61P3/06—Antihyperlipidemics
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
C07D213/26—Radicals substituted by halogen atoms or nitro radicals
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C07D213/56—Amides
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
C07J41/0011—Unsubstituted amino radicals
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
C07J41/0027—Azides
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
C07J41/0061—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives one of the carbon atoms being part of an amide group
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 – C07J43/00
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
C07K5/06—Dipeptides
C07K5/06008—Dipeptides with the first amino acid being neutral
C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K38/00—Medicinal preparations containing peptides
Abstract
Bile acid derivatives of the formula I W-X-G in which G is a bile acid residue, W is an active substance portion of a medicament and X is a linker between bile acid residue and active substance portion, are outstandingly suitable for introducing active substances into the enterohepatic circulation. The compounds I are absorbed and enter the bloodstream. This makes it possible by utilising the natural reabsorption of the bile acids to improve the absorption of drugs which are absorbed with difficulty, if at all. W can be, for example, a peptide, an antibiotic, an antiviral substance, an anticancer agent, a liver protective, an antihyperlipidaemic, a diuretic, an agent to lower blood pressure, a renin inhibitor, a substance to treat cirrhosis of the liver or a substance for treating diabetes. G is a bile acid residue in the form of the free, natural or chemically modified acids, the esters and amides, the salt forms and forms derivatised on alcohol groups. X is a large number of intermediate members or else a bond.
AU62441/90A
1989-09-14
1990-09-13
Bile acid derivatives, processes for their preparation, and use as pharmaceuticals
Expired
AU637822B2
(en)
Applications Claiming Priority (2)
Application Number
Priority Date
Filing Date
Title
DE3930696A
DE3930696A1
(en)
1989-09-14
1989-09-14
GALLENSAEUREDERIVATE, METHOD FOR THE PRODUCTION THEREOF, USE AS MEDICAMENT
DE3930696
1989-09-14
Publications (2)
Publication Number
Publication Date
AU6244190A
true
AU6244190A
(en)
1991-03-21
AU637822B2
AU637822B2
(en)
1993-06-10
Family
ID=6389405
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
AU62441/90A
Expired
AU637822B2
(en)
1989-09-14
1990-09-13
Bile acid derivatives, processes for their preparation, and use as pharmaceuticals
Country Status (21)
Country
Link
US
(3)
US5462933A
(en)
EP
(1)
EP0417725B1
(en)
JP
(3)
JP2568306B2
(en)
KR
(1)
KR0166962B1
(en)
AT
(1)
ATE152117T1
(en)
AU
(1)
AU637822B2
(en)
CA
(1)
CA2025294C
(en)
CY
(1)
CY2112B1
(en)
DE
(2)
DE3930696A1
(en)
DK
(1)
DK0417725T3
(en)
ES
(1)
ES2100858T3
(en)
FI
(1)
FI105155B
(en)
GR
(1)
GR3024095T3
(en)
HU
(1)
HU213395B
(en)
IE
(1)
IE903329A1
(en)
IL
(1)
IL95668A
(en)
NO
(1)
NO303450B1
(en)
NZ
(1)
NZ235285A
(en)
PT
(1)
PT95299B
(en)
TW
(1)
TW199097B
(en)
ZA
(1)
ZA907300B
(en)
Cited By (1)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
AU665799B2
(en)
*
1991-12-13
1996-01-18
Trustees Of Princeton University, The
Glycosylated steroid acid derivatives for transport across biological membranes
Families Citing this family (78)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
DE3930696A1
(en)
*
1989-09-14
1991-03-28
Hoechst Ag
GALLENSAEUREDERIVATE, METHOD FOR THE PRODUCTION THEREOF, USE AS MEDICAMENT
WO1992001730A1
(en)
*
1990-07-26
1992-02-06
Monsanto Company
Novel polyamines and method for preparation thereof
US5795870A
(en)
*
1991-12-13
1998-08-18
Trustees Of Princeton University
Compositions and methods for cell transformation
US5693769A
(en)
*
1991-12-13
1997-12-02
Transcell Technologies, Inc.
Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
AU664059B2
(en)
*
1991-12-20
1995-11-02
Hoechst Aktiengesellschaft
Ethylenically unsaturated bile acid derivatives, processes for their preparation and precursors
DE59205695D1
(en)
*
1991-12-20
1996-04-18
Hoechst Ag
Polymers and oligomers of bile acid derivatives, processes for their preparation and their use as medicines
JPH08511234A
(en)
*
1993-02-23
1996-11-26
ザ トラスティーズ オブ プリンストン ユニヴァーシティー
Solution and solid phase formation of glycosidic bonds
US5639866A
(en)
*
1993-02-23
1997-06-17
Princeton University
Single-step formation of multiple glycosidic linkages
TW289021B
(en)
*
1993-05-08
1996-10-21
Hoechst Ag
TW289757B
(en)
*
1993-05-08
1996-11-01
Hoechst Ag
TW289020B
(en)
*
1993-05-08
1996-10-21
Hoechst Sktiengesellschaft
IT1269839B
(en)
*
1994-05-26
1997-04-15
Bracco Spa
CONJUGATES OF BILIARY ACIDS, THEIR DERIVATIVES WITH METALLIC COMPLEXES AND RELATED USES
US5585470A
(en)
*
1994-06-23
1996-12-17
Transcell Technologies, Inc.
Process for the manufacture of 3-amino-substituted glycosylated bile acids
US5994391A
(en)
*
1994-09-13
1999-11-30
G.D. Searle And Company
Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1
(en)
1994-09-13
2001-07-31
G. D. Searle & Co.
Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US6107494A
(en)
*
1994-09-13
2000-08-22
G.D. Searle And Company
Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6262277B1
(en)
1994-09-13
2001-07-17
G.D. Searle And Company
Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2
(en)
1994-09-13
2003-11-04
G.D. Searle & Co.
Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
DE4432708A1
(en)
*
1994-09-14
1996-03-21
Hoechst Ag
Modified bile acids, process for their preparation and their use
IL142650A
(en)
*
1998-04-08
2007-06-03
Galmed Int Ltd
Use of bile acid or bile salt fatty acids conjugates for the preparation of pharmaceutical compositions for reducing cholesterol, treating fatty liver and treating hyperglycemia and diabetes
IL123998A
(en)
*
1998-04-08
2004-09-27
Galmed Int Ltd
Bile salt conjugates and pharmaceutical compositions containing them
IL139241A0
(en)
*
1998-05-13
2001-11-25
Novo Nordisk As
Meiosis regulating compounds
CN1338944A
(en)
1998-12-23
2002-03-06
G.D.瑟尔有限公司
Cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications
ES2200587T3
(en)
1998-12-23
2004-03-01
G.D. Searle Llc
COMBINATIONS OF ILEON BILIAR ACID TRANSPORTATION INHIBIDORS AND ESTER CHOLESTERILE TRANSFER PROTEIN INHIBITORS FOR CARDIOVASCULAR INDICATIONS.
IT1304501B1
(en)
*
1998-12-23
2001-03-19
Bracco Spa
USE OF BILIARY ACID DERIVATIVES CONJUGATED WITH METALLIC COMPLEXES LIKE “BLOOD POOL AGENTS” FOR THE DIAGNOSTIC INVESTIGATION THROUGH RESONANCE
US6462091B1
(en)
1998-12-23
2002-10-08
G.D. Searle & Co.
Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications
WO2000038727A1
(en)
1998-12-23
2000-07-06
G.D. Searle Llc
Combinations of ileal bile acid transport inhibitors and fibric acid derivatives for cardiovascular indications
CA2356240C
(en)
1998-12-23
2008-04-01
G.D. Searle Llc
Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
EP1140184B1
(en)
1998-12-23
2003-06-04
G.D. Searle LLC.
Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
CA2356156A1
(en)
1998-12-23
2000-07-06
G.D. Searle Llc
Combinations of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications
GB9907048D0
(en)
*
1999-03-27
1999-05-19
Karobio Ab
Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders
GB2355009A
(en)
*
1999-07-30
2001-04-11
Univ Glasgow
Peptides conjugated to bile acids/salts
US7413536B1
(en)
1999-09-14
2008-08-19
Xenoport, Inc.
Substrates and screening methods for transport proteins
DE19950686B4
(en)
*
1999-10-21
2006-06-29
Martin-Luther-Universität Halle-Wittenberg
Multifunctional Spacer
EP1286984A2
(en)
2000-03-10
2003-03-05
Pharmacia Corporation
Method for the preparation of tetrahydrobenzothiepines
US6900192B2
(en)
*
2000-10-06
2005-05-31
Xenoport, Inc.
Bile-acid conjugates for providing sustained systemic concentrations of drugs
WO2002028881A1
(en)
*
2000-10-06
2002-04-11
Xenoport, Inc.
Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration
US7144877B2
(en)
*
2000-10-06
2006-12-05
Xenoport, Inc.
Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US8975246B2
(en)
2001-04-17
2015-03-10
Galmed Research And Development Ltd.
Bile acid or bile salt fatty acid conjugates
US7053076B2
(en)
*
2001-08-29
2006-05-30
Xenoport, Inc.
Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
BR0213501A
(en)
2001-11-02
2004-08-24
Searle Llc
Mono- and difluorinated benzothiepine compounds as inhibitors of apical sodium co-dependent bile acid (asbt) transport and taurocholate uptake
MXPA04006255A
(en)
2002-01-17
2004-09-27
Pharmacia Corp
Novel alkyl/aryl hydroxy or keto thiepine compounds as inhibitors of apical sodium co-dependent bile acid transport (asbt) and taurocholate uptake.
US7141559B2
(en)
2002-06-19
2006-11-28
Karo Bio Ab
Glucocorticoid receptor ligands for the treatment of metabolic disorders
DE60309909T2
(en)
*
2002-06-19
2007-06-21
Karo Bio Ab
GLUCOCORTICOID RECEPTOR LIGANDS FOR THE TREATMENT OF METABOLISM DISORDERS
AU2003293423A1
(en)
2002-12-06
2004-06-30
Xenoport, Inc.
Carbidopa prodrugs and uses thereof
WO2004062574A2
(en)
*
2003-01-13
2004-07-29
Bracco Imaging S.P.A.
Improved linkers for radiopharmaceutical compounds
GB0307918D0
(en)
2003-04-05
2003-05-14
Astrazeneca Ab
Therapeutic use
US7205415B2
(en)
*
2004-01-02
2007-04-17
Hetero Drugs, Ltd.
Process for the preparation of simvastatin
US20080317767A1
(en)
*
2004-04-08
2008-12-25
Tobias Braxmeier
Tripartitle Raftophilic Strutures and their Use
JP4896870B2
(en)
*
2004-04-08
2012-03-14
ヤード・テヒノロギース・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Tripartite complex containing structures interacting with cell membrane rafts and uses thereof
WO2005113008A1
(en)
*
2004-05-21
2005-12-01
Mediplex Corp.
Delivery agents for enhancing mucosal absorption of therapeutic agents
WO2005118612A1
(en)
*
2004-06-04
2005-12-15
Sonus Pharmaceuticals, Inc.
Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs
EP1751087B1
(en)
2004-06-04
2012-06-27
XenoPort, Inc.
Levodopa derivatives, and compositions and uses thereof
US7323585B2
(en)
*
2004-06-04
2008-01-29
Xenoport, Inc.
Levodopa prodrugs, and compositions and uses thereof
EP1959948B1
(en)
*
2005-12-05
2012-07-18
XenoPort, Inc.
Levodopa prodrug mesylate, compositions thereof, and uses thereof
US7709527B2
(en)
2006-12-21
2010-05-04
Xenoport, Inc.
Levodopa dimethyl-substituted diester prodrugs compositions, and methods of use
US7829592B2
(en)
*
2006-12-21
2010-11-09
Xenoport, Inc.
Catechol protected levodopa diester prodrugs, compositions, and methods of use
CN101367859B
(en)
*
2007-08-17
2011-05-11
中国人民解放军军事医学科学院毒物药物研究所
Fatty acid bile acid couplet and medical uses thereof
KR101239008B1
(en)
*
2008-03-31
2013-03-04
한양대학교 산학협력단
Bile acid derivatives and their applications
JP5977945B2
(en)
*
2008-08-06
2016-08-24
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー
Conjugate proteins with long-term in vivo efficacy
US9290445B2
(en)
*
2008-10-20
2016-03-22
Xenoport, Inc.
Methods of synthesizing a levodopa ester prodrug
US8399513B2
(en)
2008-10-20
2013-03-19
Xenoport, Inc.
Levodopa prodrug mesylate hydrate
CA2747825A1
(en)
2009-01-22
2010-07-29
Novo Nordisk Health Care Ag
Stable growth hormone compounds
CN102612376A
(en)
2009-08-06
2012-07-25
诺沃-诺迪斯克保健股份有限公司
Growth hormones with prolonged in-vivo efficacy
EP2515876B1
(en)
2009-11-09
2016-01-06
XenoPort, Inc.
Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
MX338357B
(en)
2010-01-22
2016-04-13
Novo Nordisk Healthcare Ag
Stable growth hormone compounds.
AU2011208625C1
(en)
2010-01-22
2022-08-18
Novo Nordisk Health Care Ag
Growth hormones with prolonged in-vivo efficacy
EP3593802A3
(en)
2010-05-26
2020-03-25
Satiogen Pharmaceuticals, Inc.
Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
SG10201407013QA
(en)
2011-10-28
2014-12-30
Lumena Pharmaceuticals Inc
Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
SG10201406155QA
(en)
2011-10-28
2014-11-27
Lumena Pharmaceuticals Inc
Bile Acid Recycling Inhibitors For Treatment Of Pediatric Cholestatic Liver Diseases
WO2014144650A2
(en)
2013-03-15
2014-09-18
Lumena Pharmaceuticals, Inc.
Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
WO2014144485A1
(en)
2013-03-15
2014-09-18
Lumena Pharmaceuticals, Inc.
Bile acid recycling inhibitors for treatment of barrett’s esophagus and gastroesophageal reflux disease
CN105120887A
(en)
2013-04-05
2015-12-02
诺和诺德保健股份有限公司
Growth hormone compound formulation
CN104693264B
(en)
*
2015-02-09
2016-09-21
华南理工大学
A kind of compound and its preparation method and application
CN106046101B
(en)
*
2016-05-25
2018-01-05
华南理工大学
A kind of glycogen phosphorylase inhibitors and its preparation method and application
CN106496300B
(en)
*
2016-10-19
2018-05-18
上海博志研新药物技术有限公司
The preparation method of peanut cholic acid and its intermediate
US20220160726A1
(en)
2019-02-12
2022-05-26
Mirum Pharmaceuticals, Inc.
Methods for treating cholestasis
WO2023105494A1
(en)
2021-12-10
2023-06-15
Universidade Do Porto
Cationic steroid compounds, method of obtaining thereof, formulations comprising thereof and their uses
Family Cites Families (17)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US2441129A
(en)
*
1942-05-23
1948-05-11
Berczeller Arpad
Bile acid derivatives of aryl sulfonamides
US3937815A
(en)
*
1975-12-05
1976-02-10
SPA–Societa Prodotti Antibiotici S.p.A.
Lysozyme derivatives
FR2457302A1
(en)
*
1979-05-23
1980-12-19
Roussel Uclaf
NEW PROCESS FOR THE PURIFICATION OF URSODESOXYCHOLIC ACID
JPS5754151A
(en)
*
1980-09-18
1982-03-31
Takeda Chem Ind Ltd
Physiologically active substance b-52653 and its preparation
JPS57131735A
(en)
*
1981-02-09
1982-08-14
Takeda Chem Ind Ltd
Preparation of quinones
US4418059A
(en)
*
1981-07-20
1983-11-29
Montefiore Medical Center
Nucleoside ester compositions
US4499020A
(en)
*
1981-07-21
1985-02-12
Montefiore Hospital And Medical Center, Inc.
Mixed anhydrides and processes thereof
FR2511007A1
(en)
*
1981-08-07
1983-02-11
Roussel Uclaf
PROCESS FOR THE PREPARATION OF URSODESOXYCHOLIC ACID FROM 3A, 7B, 12A-TRIHYDROXYCHOLANIC ACID AND INTERMEDIATE PRODUCT USED
NL8201492A
(en)
*
1982-04-07
1983-11-01
Rijksuniversiteit
PROCESS FOR PREPARING A 4-PLACE EQUATORALLY SUBSTITUTED SYMMETRICAL-POLYCYCLETHYLENE COMPOUND; SYMMETRICAL-POLYCYCLETHYLENE COMPOUND SUBSTITUTED IN THE 4-PLACE EQUATORALLY COMPOSITION AND A THERMOCHEMILUMINUM SCREENING PROCESS MATERIAL PREPARED ON THE BASIS OF THE COMPOUND.
EP0105404A1
(en)
*
1982-09-30
1984-04-18
Merck & Co. Inc.
Derivatives of steroid compounds linked to cyotoxic agents and process for their preparation
DE3432094A1
(en)
*
1984-08-31
1986-03-06
Hoechst Ag, 6230 Frankfurt
ESTER OF PYRIDINE-2,4- AND -2,5-DICARBONIC ACID AS A MEDICINAL PRODUCT FOR INHIBITING PROLIN AND LYSINE HYDROXYLASE
JPS62175497A
(en)
*
1986-01-28
1987-08-01
Wakunaga Pharmaceut Co Ltd
Bile acid derivative and production thereof
US5238948A
(en)
*
1987-02-10
1993-08-24
Hoechst Aktiengesellschaft
Pyridine-2,4- and -2,5-dicarboxylic acid derivatives and medicaments based on these compounds
FI90236C
(en)
*
1987-07-10
1994-01-10
Hoechst Ag
Process for the preparation of therapeutically useful 3-desmethylmevalonic acid derivatives
US4968790A
(en)
*
1988-08-12
1990-11-06
American Cyanamid Company
Antidiabetic phosphates
DE3930696A1
(en)
*
1989-09-14
1991-03-28
Hoechst Ag
GALLENSAEUREDERIVATE, METHOD FOR THE PRODUCTION THEREOF, USE AS MEDICAMENT
DE3931432A1
(en)
*
1989-09-21
1991-04-04
Hoechst Ag
PYRIMIDIN-4,6-DICARBONSAEUREDIAMIDE, METHOD FOR THE PRODUCTION AND USE THEREOF AND MEDICINAL PRODUCTS BASED ON THESE COMPOUNDS
1989
1989-09-14
DE
DE3930696A
patent/DE3930696A1/en
not_active
Withdrawn
1990
1990-09-11
AT
AT90117470T
patent/ATE152117T1/en
not_active
IP Right Cessation
1990-09-11
EP
EP90117470A
patent/EP0417725B1/en
not_active
Expired – Lifetime
1990-09-11
DE
DE59010706T
patent/DE59010706D1/en
not_active
Expired – Lifetime
1990-09-11
DK
DK90117470.6T
patent/DK0417725T3/en
active
1990-09-11
ES
ES90117470T
patent/ES2100858T3/en
not_active
Expired – Lifetime
1990-09-12
FI
FI904497A
patent/FI105155B/en
active
IP Right Grant
1990-09-12
IL
IL9566890A
patent/IL95668A/en
unknown
1990-09-12
NZ
NZ235285A
patent/NZ235285A/en
unknown
1990-09-13
AU
AU62441/90A
patent/AU637822B2/en
not_active
Expired
1990-09-13
NO
NO903999A
patent/NO303450B1/en
not_active
IP Right Cessation
1990-09-13
JP
JP2241338A
patent/JP2568306B2/en
not_active
Expired – Lifetime
1990-09-13
HU
HU905893A
patent/HU213395B/en
unknown
1990-09-13
PT
PT95299A
patent/PT95299B/en
not_active
IP Right Cessation
1990-09-13
IE
IE332990A
patent/IE903329A1/en
not_active
IP Right Cessation
1990-09-13
CA
CA002025294A
patent/CA2025294C/en
not_active
Expired – Lifetime
1990-09-13
ZA
ZA907300A
patent/ZA907300B/en
unknown
1990-09-14
KR
KR1019900014542A
patent/KR0166962B1/en
not_active
IP Right Cessation
1990-09-14
TW
TW079107732A
patent/TW199097B/zh
active
1994
1994-03-10
US
US08/208,192
patent/US5462933A/en
not_active
Expired – Lifetime
1995
1995-06-07
US
US08/476,941
patent/US5646272A/en
not_active
Expired – Lifetime
1995-06-07
US
US08/475,689
patent/US5668126A/en
not_active
Expired – Lifetime
1995-09-07
JP
JP7254512A
patent/JP2642090B2/en
not_active
Expired – Lifetime
1995-09-07
JP
JP7254511A
patent/JP2642089B2/en
not_active
Expired – Lifetime
1997
1997-07-15
GR
GR970401746T
patent/GR3024095T3/en
unknown
1998
1998-09-29
CY
CY9800029A
patent/CY2112B1/en
unknown
Cited By (1)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
AU665799B2
(en)
*
1991-12-13
1996-01-18
Trustees Of Princeton University, The
Glycosylated steroid acid derivatives for transport across biological membranes
Also Published As
Publication number
Publication date
JP2642089B2
(en)
1997-08-20
ATE152117T1
(en)
1997-05-15
GR3024095T3
(en)
1997-10-31
US5646272A
(en)
1997-07-08
EP0417725A2
(en)
1991-03-20
KR910006319A
(en)
1991-04-29
NO303450B1
(en)
1998-07-13
DK0417725T3
(en)
1997-11-03
IE903329A1
(en)
1991-04-10
FI105155B
(en)
2000-06-30
ES2100858T3
(en)
1997-07-01
JP2642090B2
(en)
1997-08-20
PT95299B
(en)
1997-06-30
JPH0892277A
(en)
1996-04-09
KR0166962B1
(en)
1999-01-15
HU213395B
(en)
1997-06-30
DE3930696A1
(en)
1991-03-28
PT95299A
(en)
1991-05-22
IL95668A
(en)
1995-03-30
US5462933A
(en)
1995-10-31
NO903999L
(en)
1991-03-15
US5668126A
(en)
1997-09-16
NO903999D0
(en)
1990-09-13
EP0417725B1
(en)
1997-04-23
AU637822B2
(en)
1993-06-10
JP2568306B2
(en)
1997-01-08
CA2025294A1
(en)
1991-03-15
EP0417725A3
(en)
1992-03-18
FI904497A0
(en)
1990-09-12
CA2025294C
(en)
2001-11-27
HUT56115A
(en)
1991-07-29
JPH03109396A
(en)
1991-05-09
IL95668A0
(en)
1991-06-30
NZ235285A
(en)
1993-05-26
ZA907300B
(en)
1991-06-26
HU905893D0
(en)
1991-03-28
JPH0892276A
(en)
1996-04-09
CY2112B1
(en)
2002-04-26
TW199097B
(en)
1993-02-01
DE59010706D1
(en)
1997-05-28
Similar Documents
Publication
Publication Date
Title
AU6244190A
(en)
1991-03-21
Bile acid derivatives, processes for their preparation, and use as pharmaceuticals
AU649089B2
(en)
1994-05-12
Bile acid derivatives, process for their preparation and use of these compounds as pharmaceuticals
AU2368688A
(en)
1989-04-20
Polysulfuric acid esters of bis-aldonamides and their derivatives, process for their preparation and medicaments
ES2001512A6
(en)
1988-06-01
New polysaccharide esters and their salts.
UA41446C2
(en)
2001-09-17
Use of fumagilol or its derivatives for preparing drugs intended for treating intestinal infection and pharmaceutical composition
CA2173582A1
(en)
1995-04-13
Nitric esters having anti-inflammatory and/or analgesic activity and process for their preparation
EP0747092A3
(en)
1998-04-08
Dissolution liquid for drug in iontophoresis
HK129393A
(en)
1993-12-03
Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus
RU94040170A
(en)
1996-10-10
Isoquinolines
Bourget et al.
1985
Phenylalanine ammonia‐lyase immobilized in semipermeable microcapsules for enzyme replacement in phenylketonuria
CA2547990A1
(en)
2005-06-23
Pharmaceutical compositions and methods for insulin treatment
WO1997029745B1
(en)
1997-09-25
Zwitterionic compositions and methods as biological response modifiers
DE3676335D1
(en)
1991-02-07
PHARMACEUTICAL COMPOSITIONS BASED ON MERCAPTOETHANESULPHONIC ACIDS, ORGANIC COMBATINGS OF MERCAPTOETHANESULPHONIC ACIDS AND METHOD FOR THE PRODUCTION THEREOF.
ATE52791T1
(en)
1990-06-15
IN ITEM B 30 MODIFIED INSULIN DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AND PHARMACEUTICAL AGENTS FOR THE TREATMENT OF DIABETES MELLITUS.
JPS5780314A
(en)
1982-05-19
Pharmaceutical preparation to be medicated to rectum
JPH04275234A
(en)
1992-09-30
Percutaneous absorption-promoting agent
RU94037232A
(en)
1996-06-20
Peptides showing organ-protective activity, method of their synthesis and their use
HU901875D0
(en)
1990-07-28
Process for production of galenical preparations providing optimal biological accessibility of 2-hydroxi-5-methyl-laurophenon-oxim as active substance
JPS57163317A
(en)
1982-10-07
Stabilizing agent for peptide hormone
IT1226144B
(en)
1990-12-19
Phosphoric di-ester of ursodeoxycholic acid and its derivatives, process for their preparation and therapeutic compositions which contain them as active substances
None